Published in Proc Natl Acad Sci U S A on June 23, 2010
In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles. J Control Release (2013) 1.11
Minireview: animal models and mechanisms of ovarian cancer development. Endocrinology (2012) 1.04
Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci U S A (2012) 1.03
α(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug. ACS Nano (2012) 1.00
Cisplatin-loaded core cross-linked micelles: comparative pharmacokinetics, antitumor activity, and toxicity in mice. Int J Nanomedicine (2012) 0.91
Nano delivers big: designing molecular missiles for cancer therapeutics. Pharmaceutics (2011) 0.91
Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy. Nanotechnology (2011) 0.88
Metals and breast cancer: risk factors or healing agents? J Toxicol (2011) 0.88
Nanoparticle formulations of cisplatin for cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.85
Dawn of advanced molecular medicine: nanotechnological advancements in cancer imaging and therapy. Crit Rev Oncog (2014) 0.81
Development of EGFR-targeted nanoemulsion for imaging and novel platinum therapy of ovarian cancer. Pharm Res (2014) 0.81
Sequential application of a cytotoxic nanoparticle and a PI3K inhibitor enhances antitumor efficacy. Cancer Res (2013) 0.78
Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy. Nanotechnology (2012) 0.78
Reporter nanoparticle that monitors its anticancer efficacy in real time. Proc Natl Acad Sci U S A (2016) 0.78
Efficacy of polyMPC-DOX prodrugs in 4T1 tumor-bearing mice. Mol Pharm (2014) 0.77
Organometallic cis-Dichlorido Ruthenium(II) Ammine Complexes. Eur J Inorg Chem (2011) 0.77
Design, synthesis, and evaluation of cisplatin-containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumors. Onco Targets Ther (2016) 0.77
Convection enhanced delivery of cisplatin-loaded brain penetrating nanoparticles cures malignant glioma in rats. J Control Release (2017) 0.77
Synthesis of anti-inflammatory α-and β-linked acetamidopyranosides as inhibitors of toll-like receptor 4 (TLR4). Tetrahedron Lett (2015) 0.76
Engineering Biomaterial-Drug Conjugates for Local and Sustained Chemotherapeutic Delivery. Bioconjug Chem (2015) 0.76
EGFR Targeted Theranostic Nanoemulsion for Image-Guided Ovarian Cancer Therapy. Pharm Res (2015) 0.76
Systemic Delivery and Biodistribution of Cisplatin in Vivo. Mol Pharm (2016) 0.75
Drug delivery systems for ovarian cancer treatment: a systematic review and meta-analysis of animal studies. PeerJ (2015) 0.75
MR image-guided delivery of cisplatin-loaded brain-penetrating nanoparticles to invasive glioma with focused ultrasound. J Control Release (2017) 0.75
Platinum nanoparticles induce damage to DNA and inhibit DNA replication. PLoS One (2017) 0.75
New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth. Breast Cancer Res Treat (2017) 0.75
Electrohydrodynamic fabrication of core-shell PLGA nanoparticles with controlled release of cisplatin for enhanced cancer treatment. Int J Nanomedicine (2017) 0.75
Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer (2005) 13.49
Renal clearance of quantum dots. Nat Biotechnol (2007) 12.54
The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer (2007) 12.38
Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev (2001) 10.02
The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A (2008) 7.06
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res (1995) 6.21
Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem Rev (1999) 5.63
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res (2006) 4.99
Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med (2004) 4.98
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A (2008) 3.62
Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res (1994) 3.54
Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol (1999) 3.15
Intravascular delivery of particulate systems: does geometry really matter? Pharm Res (2008) 3.13
The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest (2007) 2.71
Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell (2002) 2.67
PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release (2002) 2.26
Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res (1998) 2.07
Platinum nephrotoxicity. Am J Med (1978) 1.73
Solution structure of a cisplatin-induced DNA interstrand cross-link. Science (1995) 1.70
Nanotechnology and the developing world. PLoS Med (2005) 1.66
Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol (1996) 1.43
A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res (2004) 1.14
Polymeric drug delivery of platinum-based anticancer agents. J Pharm Sci (2009) 1.13
Cisplatin incorporated in microspheres: development and fundamental studies for its clinical application. J Control Release (2003) 1.08
K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients. Cancer (1998) 1.08
Improved targeting of platinum chemotherapeutics. the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models. Eur J Cancer (2004) 1.00
Shape effect of carbon nanovectors on angiogenesis. ACS Nano (2010) 0.94
A comparison of in vitro platinum-DNA adduct formation between carboplatin and cisplatin. Int J Biochem (1994) 0.89
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A (2006) 4.66
A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med (2007) 3.96
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell (2011) 3.88
Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle (2007) 3.62
India's R&D: reaching for the top. Science (2005) 2.08
Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A (2012) 1.81
Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. Cancer Prev Res (Phila) (2009) 1.75
Rapid self-healing hydrogels. Proc Natl Acad Sci U S A (2012) 1.29
Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res (2006) 1.22
Overexpression of Cdc20 leads to impairment of the spindle assembly checkpoint and aneuploidization in oral cancer. Carcinogenesis (2006) 1.19
Focused glycomic analysis of the N-linked glycan biosynthetic pathway in ovarian cancer. Proteomics (2008) 1.17
Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. PLoS One (2009) 1.17
p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. Anticancer Res (2009) 1.13
Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proc Natl Acad Sci U S A (2009) 1.06
Abnormal SDS-PAGE migration of cytosolic proteins can identify domains and mechanisms that control surfactant binding. Protein Sci (2012) 1.06
Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci U S A (2012) 1.03
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci U S A (2006) 1.02
Fullerenol-cytotoxic conjugates for cancer chemotherapy. ACS Nano (2009) 0.99
Coupling growth-factor engineering with nanotechnology for therapeutic angiogenesis. Proc Natl Acad Sci U S A (2010) 0.99
A systematic analysis of peptide linker length and liposomal polyethylene glycol coating on cellular uptake of peptide-targeted liposomes. ACS Nano (2013) 0.96
Medical implications of benzimidazole derivatives as drugs designed for targeting DNA and DNA associated processes. Curr Med Chem (2008) 0.96
Shape effect of carbon nanovectors on angiogenesis. ACS Nano (2010) 0.94
Inhibition of weak-affinity epitope-IgE interactions prevents mast cell degranulation. Nat Chem Biol (2013) 0.94
Ranking chemical structures for drug discovery: a new machine learning approach. J Chem Inf Model (2010) 0.91
Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis (2009) 0.90
Endothelial cells preparing to die by apoptosis initiate a program of transcriptome and glycome regulation. FASEB J (2003) 0.90
Synthetic allergen design reveals the significance of moderate affinity epitopes in mast cell degranulation. ACS Chem Biol (2012) 0.90
Insulin-like growth factors promote vasculogenesis in embryonic stem cells. PLoS One (2012) 0.89
Design of a heterotetravalent synthetic allergen that reflects epitope heterogeneity and IgE antibody variability to study mast cell degranulation. Biochem J (2013) 0.89
Delivery of therapeutic levels of heparin and low-molecular-weight heparin through a pulmonary route. Proc Natl Acad Sci U S A (2004) 0.89
Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy. Nanotechnology (2011) 0.88
Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells. BMC Cancer (2012) 0.86
Single-walled carbon nanotube-conjugated chemotherapy exhibits increased therapeutic index in melanoma. Nanotechnology (2009) 0.85
Emp is a component of the nuclear matrix of mammalian cells and undergoes dynamic rearrangements during cell division. Biochem Biophys Res Commun (2006) 0.85
Nanotechnology-mediated targeting of tumor angiogenesis. Vasc Cell (2011) 0.85
New paradigms in the repair of oxidative damage in human genome: mechanisms ensuring repair of mutagenic base lesions during replication and involvement of accessory proteins. Cell Mol Life Sci (2015) 0.83
Selective photocrosslinking of functional ligands to antibodies via the conserved nucleotide binding site. Biomaterials (2013) 0.83
Small-molecule-based affinity chromatography method for antibody purification via nucleotide binding site targeting. Anal Chem (2012) 0.82
Genomic instabilities in squamous cell carcinoma of head and neck from the Indian population. Mol Carcinog (2006) 0.81
Enhanced cellular uptake of peptide-targeted nanoparticles through increased peptide hydrophilicity and optimized ethylene glycol peptide-linker length. ACS Nano (2013) 0.81
Neutralizing positive charges at the surface of a protein lowers its rate of amide hydrogen exchange without altering its structure or increasing its thermostability. J Am Chem Soc (2010) 0.81
Oriented surface immobilization of antibodies at the conserved nucleotide binding site for enhanced antigen detection. Langmuir (2012) 0.81
PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic. Cell Oncol (Dordr) (2013) 0.79
Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo. J Med Chem (2014) 0.79
Symmetrical bisbenzimidazoles with benzenediyl spacer: the role of the shape of the ligand on the stabilization and structural alterations in telomeric G-quadruplex DNA and telomerase inhibition. Bioconjug Chem (2010) 0.79
Targeting oncogenic signaling pathways by exploiting nanotechnology. Cell Cycle (2009) 0.79
A heterobivalent ligand inhibits mast cell degranulation via selective inhibition of allergen-IgE interactions in vivo. J Immunol (2014) 0.78
Improved Peptide-Targeted Liposome Design Through Optimized Peptide Hydrophilicity, Ethylene Glycol Linker Length, and Peptide Density. J Biomed Nanotechnol (2015) 0.78
Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy. Nanotechnology (2012) 0.78
"Take it up a NOTCH": novel strategies for cancer therapy. Cell Cycle (2012) 0.78
Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy. Cancer Res (2013) 0.78
Photosensitive Pt(IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo. J Control Release (2014) 0.78
Affinity-based precipitation via a bivalent peptidic hapten for the purification of monoclonal antibodies. Analyst (2014) 0.78
Oriented antibody immobilization by site-specific UV photocrosslinking of biotin at the conserved nucleotide binding site for enhanced antigen detection. Biosens Bioelectron (2013) 0.77
The dynamic glycome microenvironment and stem cell differentiation into vasculature. Stem Cells Dev (2011) 0.76
Nanoparticles in cancer chemotherapy. Prog Mol Biol Transl Sci (2011) 0.76
Nonchromatographic affinity precipitation method for the purification of bivalently active pharmaceutical antibodies from biological fluids. Anal Chem (2013) 0.76
Micellar nanoparticle formation via electrostatic interactions for delivering multinuclear platinum(II) drugs. Chem Commun (Camb) (2013) 0.76
Anti-platelet agents augment cisplatin nanoparticle cytotoxicity by enhancing tumor vasculature permeability and drug delivery. Nanotechnology (2014) 0.76
Emerging technologies for enabling proangiogenic therapy. Nanotechnology (2011) 0.76
P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer. Med Oncol (2013) 0.76
Functionalized liposome purification via Liposome Extruder Purification (LEP). Analyst (2013) 0.76
Metal-ion-mediated tuning of duplex DNA binding by bis(2-(2-pyridyl)-1H-benzimidazole). Chem Asian J (2007) 0.75
Conjugation of a reactive thiol at the nucleotide binding site for site-specific antibody functionalization. Bioconjug Chem (2014) 0.75
Cancer, signal transduction and nanotechnology. Curr Drug Deliv (2011) 0.75
What potential do heterobivalent inhibitors have for the treatment of severe allergic reactions? Immunotherapy (2014) 0.75
Site-specific conjugation of an antibody on a gold nanoparticle surface for one-step diagnosis of prostate specific antigen with dynamic light scattering. Nanoscale (2017) 0.75
Evaluation of DNA degradation using flow cytometry: promising tool for postmortem interval determination. Am J Forensic Med Pathol (2015) 0.75